Moxifloxacino Aurovitas (Moxifloxacin Hydrochloride)

Moxifloxacin inhibits bacterial DNA gyrase and topoisomerase IV, enzymes required for DNA replication and transcription. This inhibition halts bacterial cell division, leading to a bactericidal effect against a broad spectrum of Gram‑positive and Gram‑negative organisms.

The dosage of Moxifloxacino Aurovitas is determined by the prescribing clinician based on the infection type, severity, patient age, renal function, and other clinical factors. The prescriber will select the appropriate strength and regimen for each individual case.

Safety data for moxifloxacin in pregnancy and lactation are limited. It should only be used when the potential benefit justifies the potential risk to the fetus or infant, and only under the guidance of a qualified healthcare professional.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Moxifloxacino Aurovitas offers a broader spectrum of activity, particularly against atypical respiratory pathogens, compared with older fluoroquinolones such as ciprofloxacin. It also has a lower propensity for certain drug‑resistance mechanisms, though safety considerations like QT prolongation remain similar across the class.

Store the tablets at temperatures below 25 °C, in the original packaging, and protect them from moisture and direct sunlight. Do not store in bathrooms or near heat sources, and keep out of reach of children.

Moxifloxacino Aurovitas is taken orally as a tablet. Swallow the tablet whole with a glass of water; it may be taken with or without food, unless the prescriber advises otherwise.

Serious risks include tendon rupture (especially the Achilles tendon), QT interval prolongation leading to cardiac arrhythmias, severe allergic reactions such as anaphylaxis, Clostridioides difficile‑associated colitis, hepatic toxicity, and rare skin reactions like Stevens‑Johnson syndrome.

Patients with a known hypersensitivity to moxifloxacin or any fluoroquinolone should avoid the product. It is also contraindicated in individuals with a history of tendon disorders related to fluoroquinolone use, those with significant QT prolongation, and patients receiving other medications that markedly increase the risk of tendon rupture or cardiac arrhythmias.